Issue Date: July 2, 2007
THE SUPREME COURT'S ruling is rather ridiculous (C&EN, May 7, page 13). Because of the complexity of some racemates, resolving them into the component stereoisomers is no easy task. Any company that succeeds in this process deserves a patent, not just a process patent but a patent on the active isomer. This presumes that the other isomer will not be found "effective" for some other use and approved by the Food & Drug Administration, actually doing more harm than good.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society